Introduction
Sickle cell disease (SCD) is a relatively common inherited blood disorder that affects millions of people worldwide (1) . When deoxygenated, the sickle hemoglobin tetramer polymerizes to form a network of fibrous polymers that cause erythrocytes to acquire a sickle shape. Sickleshaped erythrocytes then cause microvascular occlusions that lead to painful crises and can adversely affect kidney function in many ways (1) . Approximatively 4% of cases of sickle cell anemia develop into kidney failure that requires dialysis or kidney transplantation (2) . The long-term survival of these patients is dramatically decreased compared with that of kidney transplant recipients without SCD (3).
In patients with SCD, the control of hemoglobin level, associated with the decrease in sickle hemoglobin and the increase in fetal hemoglobin, is the cornerstone of treatment to improve the acute and chronic hemolytic lesions and the vaso-occlusive complications of the disease (1). Hydroxyurea, a ribonucleotide reductase inhibitor, is effective in reducing increased sickle hemoglobin and can increase fetal hemoglobin levels; it can also decrease pain and reduce microalbuminuria (4). However, this treatment often cannot avoid the symptoms related to SCD, including the reoccurrence of SCD on the transplant.
The mammalian target of rapamycin (mTOR) is a kinase that integrates a variety of signaling pathways (principally with two cellular complexes: MTORC-1 and MTORC-2), which regulate cellular growth, proliferation, and survival. The mTOR inhibitors, such as sirolimus or everolimus, are frequently used in immunosuppressive treatments after solid organ transplantation to prevent rejection and to avoid renal dysfunction related to the use of calcineurin inhibitors or for their antiviral or antineoplastic effects (5, 6) . Recently, the role of mTOR inhibitors to increase hemoglobin and fetal hemoglobin levels in erythrocytes was highlighted in vitro (7, 8) but also in murine models of SCD (9) .
Case Description
A 35-year-old patient, who was a native of Democratic Republic of the Congo, arrived in France in 2011. He had hemoblogulin SS sickle cell anemia, complicated by chronic kidney disease that required dialysis in 2012. Hydroxyurea was introduced rapidly after dialysis (500 mg, three times weekly, as recommended with dialysis), associated with high doses of recombinant erythropoietin and blood exchange transfusions to control hemoglobin, sickle hemoglobin, and fetal hemoglobin levels ( Figure 1 ).
In November 2013, the patient presented with regular and painful vaso-occlusive crises and acute chest syndrome. The patient received a first kidney transplant from a deceased donor in August 2015. He received a blood transfusion just before surgery to obtain a sickle hemoglobin rate of <50% (Figure 1 ). After transplantation, he received induction therapy with basiliximab (20 mg on days 1 and 4) followed by triple sequential therapy of tacrolimus (target trough level: 6-8 ng/mL), mycophenolate mofetil (1000 g/day), and low-dose steroids. The initial postoperative period was uneventful with rapid recovery of kidney function. At 1 week posttransplantation, renal function became normal (blood creatinine levels: 1.1 mg/dL) and remained stable until the last follow-up.
The dose of hydroxyurea was increased to 500 mg twice/ day according to renal function, and recombinant erythropoietin was maintained (with hemoglobin targeted at 8-10 g/dL). At 4 months posttransplantation, the patient presented with a painful vaso-occlusive crises that required hospitalization and a red blood cell transfusion. Hemoglobin, sickle hemoglobin, and fetal hemoglobin rates were 8 g/dL, 63%, and 4.8%, respectively. A switch from mycophenolate mofetil to mTOR inhibitors was implemented. Everolimus was started at 0.75 mg twice/ day and was well supported. All others medications were unchanged. Thereafter, everolimus dose was increased to obtain a trough level of 4-6 ng/mL (Figure 1 ).
During the follow-up, the dosage of tacrolimus remained at 18 mg/day to obtain a trough level of 5-10 ng/mL (Figure 1) . The patient also received prednisone (5 mg/day) and hydroxyurea therapy at 500 mg twice/day. The patient did not receive any other medications, except for acetaminophen, if necessary. At the last follow-up, at 16 months posttransplantation (10 months after introducing everolimus), the patient had no further vaso-occlusive crises or need for a blood transfusion. We also saw a clear and stable improvement in hemoglobin and fetal hemoglobin levels (Figure 1) , whereas sickle hemoglobin levels remained stable at close to 80%. At the last follow-up, fetal hemoglobin level was stable at~15%. Of note, the albuminuria:creatininuria ratio was physiological (16 mg/g) at the last follow-up (16 months after kidney transplantation).
Discussion
Fetal hemoglobin is synthesized throughout life and reflects the products of c-globulin genes (10). In healthy adults, fetal hemoglobin represents <1% of total hemoglobin (10) . Pharmacologically mediated stimulation of human c-globulin gene expression is a potential approach to improve fetal hemoglobin levels.
It has been previously shown that the mTOR pathway is involved in regulating the growth and proliferation of red blood cells, both in vitro and in vivo. The mTOR complex 1 pathway has been identified as a critical regulator of red blood cell growth and proliferation (11) (12) (13) . The use of mTOR inhibitors in normal and b-thalassemia patients has increased; in vitro, the expression of fetal hemoglobin is increased to higher levels than those obtained with hydroxyurea (8).
It has also been shown that rapamycin promotes the accumulation of c-globulin mRNA in erythroid progenitor cells (7) . The mechanism by which rapamycin induces cglobulin mRNA is only partially known, but the induction of erythroid by rapamycin is associated with decreased phosphorylation of a-p-S6 (a ribosomal protein that influences cell size) and hyperphosphorylation of 4E-BP-1 (a protein that regulates cell proliferation) (12) , with these two proteins involved in erythropoiesis (12) . Moreover, mTOR inhibition was shown to improve anemia in a urine model of SCD (9).
In our patient, the use of everolimus with tacrolimus was well tolerated and effective and avoided an acute rejection. Moreover, as expected with in vitro studies (8, 14) , where rapamycin was associated with improved fetal hemoglobin and somatosensory function, fetal hemoglobin rate was clearly increased and the patient had reduced pain related to SCD, even though the sickle hemoglobin level was high.
This case report has some limitations. First, it was difficult to assess the use of mTOR inhibitors in only one patient. Fetal hemoglobin rates and pain related to SCD were reduced with the use of everolimus, but we cannot exclude that this was coincidental. However, the significant increase in fetal hemoglobin soon after introducing everolimus, as well as the published results from in vitro studies, favors a link between treatment with mTOR inhibitors and the biological effects observed here.
After kidney transplantation, the use of mTOR inhibitors has been associated with higher rates of anemia (15) . However, sickle cell anemia is characterized as being a disease in which ineffective erythropoiesis contributes to the severity of the disease: consequently, mTOR inhibition may then potentially reduce this effect. Moreover, it has been previously shown that mTOR inhibitors can induce proteinuria (16) and thromboembolic disease (17) , which could have serious consequences for graft recipients with SCD. Here, the association of low doses of everolimus (trough level 4-6 ng/mL) and tacrolimus was well tolerated, without causing complications.
Conclusion
mTOR inhibitors associated with hydroxyurea given to a patient who had undergone kidney transplantation and had SCD seemed to improve clinical and biological outcomes. Larger prospective studies are required to confirm this finding.
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